Codexis Strengthens Workforce with New Equity Grants
Codexis, Inc. (NASDAQ: CDXS), recognized as a front-runner in enzymatic solutions for scalable therapeutics manufacturing, recently announced the approval of equity grants aimed at five newly hired employees. These grants were ratified by the Compensation Committee of Codexis’ Board of Directors to encourage new talent to join their innovative team.
Details of the Equity Awards Offered
The newly onboarded employees will receive a combination of equity awards consisting of options to purchase a total of 168,400 shares of Codexis common stock along with 39,750 restricted stock units (RSUs) as part of the 2024 Inducement Plan designed to attract top talent. Such grants not only serve as a reward but also align the interests of the employees with that of shareholders, fostering a robust company culture dedicated to growth and innovation.
Structure of Stock Options
The stock options awarded feature an exercise price that mirrors the closing price per share on the grant date achieved by Codexis as reported by Nasdaq. These options will vest over four years, with a quarter of the shares vesting on the first anniversary of the vesting start date. The remaining shares will vest monthly thereafter as long as the employees remain with Codexis.
Insight into Restricted Stock Units
The granted RSUs will vest in equal amounts over three years, with annual installments occurring each anniversary after the grant date. This structure encourages sustained commitment from employees, fostering a stable and engaged workforce that contributes to the long-term objectives of Codexis.
Codexis: Innovating Therapeutics Manufacturing
Codexis is renowned for its proprietary CodeEvolver technology platform, which facilitates the discovery and enhancement of high-performance enzymes and proteins. Their innovative enzymes address significant challenges in small molecule pharmaceuticals manufacturing and the synthesis of nucleic acids. Current initiatives include the development of the proprietary ECO Synthesis manufacturing platform, which aims to advance RNAi therapeutics through an enzymatic approach, leveraging Codexis’ unique capabilities.
Benefits of Codexis Enzymatic Solutions
Codexis' enzymes offer remarkable improvements in various aspects of therapeutics manufacturing, including increased yield, decreased energy consumption, and minimized waste production. These enhancements not only bolster manufacturing processes but also enhance sensitivity in genomic and diagnostic applications, positioning Codexis as a leader in the field.
Contact Information for Partners
For those interested in partnership opportunities or further information, Codexis provides accessible contact options. Investors can reach out to Carrie McKim, with inquiries directed to (336) 608-9706 or via email at ir@codexis.com. For media-related questions, Lauren Musto can be contacted at (650) 421-8205 or through email at media@codexis.com.
Frequently Asked Questions
What type of equity grants did Codexis approve?
Codexis approved options to purchase 168,400 shares of stock and 39,750 RSUs for new employees.
How long will it take for the stock options to vest?
The stock options will vest over four years, with 25 percent vesting on the first anniversary of the commencement date.
What is the purpose of granting RSUs?
RSUs vest over three years to encourage employee retention and alignment with the company's long-term goals.
What platform is Codexis developing for RNAi therapeutics?
Codexis is developing its proprietary ECO Synthesis manufacturing platform for RNAi therapeutics through an enzymatic route.
How can I contact Codexis for more information?
You can contact Carrie McKim or Lauren Musto via the emails provided or by phone for investor and media inquiries, respectively.
